Diagnostic and pathogenetic role of antineutrophil cytoplasmic autoantibodies

Clinical Immunology

Volumn 106, Issue 2, 2003, Pages 73-82

  Bartůňková, Jiřina ^a   Tesař, Vladimír ^b   Šedivá, Anna ^a  

^a UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Adults; Antineutrophil cytoplasmic antibodies; Children; Diagnostic association; Etiopathogenesis

Indexed keywords

CELL ADHESION MOLECULE; CYTOKINE; NEUTROPHIL CYTOPLASMIC ANTIBODY;

ANTIBODY TITER; ANTIGEN RECOGNITION; ANTIMICROBIAL ACTIVITY; CORRELATION ANALYSIS; CORRELATION FUNCTION; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE ACTIVITY; DISEASE ASSOCIATION; ENVIRONMENTAL FACTOR; HEREDITY; HUMAN; INFLAMMATION; LABORATORY TEST; LEUKOCYTE FUNCTION; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PATHOGENICITY; PRIORITY JOURNAL; RESPIRATORY BURST; REVIEW; SIGNAL TRANSDUCTION; VASCULITIS;

EID: 0345700236     PISSN: 15216616     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1521-6616(02)00026-8     Document Type: Review

References (118)

1. Wiik A., Jensen E., Friis J. Granulocyte-specific antinuclear factors in synovial fluids and sera from patients with rheumatoid arthritis. Ann. Rheum. Dis. 33:1974;515-522.
2. Davies D.J., Moran J.E., Nial J.F., Ryan G.B. Segmental necrotizing glomerulonephritis with antineutrophil antibody possible arbovirus aetiology? Br. Med. J. 265:1982;606-608.
3. Hall J.B., Wadham B.M., Wood C.J., Ashton V., Adam W.R. Vasculitis and glomerulonephritis a subgroup with an antineutrophil cytoplasmic antibody . Aust. N. Z. J. Med. 14:1984;277-278.
4. Van der Woude F.J., Rasmussen N., Lobatto S., Wiik A., Permin H., van Es L.A. Autoantibodies against neutrophils and monocytes tool for diagnosis and marker of disease activity in Wegener's granulomatosis . Lancet. i:1985;425-429.
5. Jenne D.E., Tschopp J., Lüdemann J., et al. Wegener's autoantigen decoded. Nature. 346:1990;520.
6. Falk A.J., Jennette J.C. Antineutrophil cytoplasmic autoantibodies with specificity for myeoloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis. N. Engl. J. Med. 318:1988;1651-1657.
7. Wiik A. Delineation of a standard procedure for indirect immunofluorescence detection of ANCA. Acta Pathol. Microbiol. Immunol. Scand. Suppl. 6:1989;12-15.
8. Lesavre P., Noel L.H., Chauveau D., Geffriaud C., Grunfeld J.P. Antigen specificities and clinical distribution of ANCA in kidney diseases. Klin. Wochenschrift. 69:1991;552-557.
9. Kallenberg C.G.M. Antineutrophil cytoplasmic antibodies, current diagnostic and pathophysiological potential. Kidney Int. 46:1994;1-15.
10. Gross W.L., Schmitt W.H., Csernok E. ANCA and associated diseases, imunodiagnostic and pathogenic aspects. Clin. Exp. Immunol. 91:1993;1-12.
11. Wiik A., Stummann L., Kjeldsen L. The diversity of perinuclear antineutrophil cytoplasmic antibodies (pANCA) antigens. Clin. Exp. Immunol. 101:(Suppl. 1):1995;15-17.
12. Zhao M.H., Jayne D.R.W., Ardiles L., Culley F., Hodson M.E., Lockwood C.M. Autoantibodies against bactericidal/permeability-increasing protein (BPI) in cystic fibrosis. Clin. Exp. Immunol. 101:(Suppl. 1):1995;38.
13. Roozendaal C., Zhao M.H., Horst G. Catalase and alpha-enolase two novel granulocyte autoantigens in inflammatory bowel diseases . Clin. Exp. Immunol. 112:1998;10-16.
14. Sobajima J., Ozaki S., Osakada F. Novel autoantigens of perinuclear anti-neutrophil cytoplasmic antibodies (p-ANCA) in ulcerative colitis, non histone chromosomal proteins, HMG 1 and HMG 2. Clin. Exp. Immunol. 107:1997;135-140.
15. Jennette J.C., Falk R.J. Clinical and pathological classification of ANCA-associated vasculitis what are the controversies? Clin. Exp. Immunol. 101:1995;18-22.
16. Nölle B., Specks V., Lüdermann J., Rohrbach M.S., De Remee R.A., Gross W.L. Anticytoplasmic autoantibodies their immunodiagnostic value in Wegener's granulomatosis . Ann. Intern. Med. 111:1989;28-40.
17. Boomsma M.M., Stegeman C.A., van der Leij M.J., Oost W., Hermans J., Kallenberg C.G., LimburgCohen P.C., Tervaert J.W. Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels a prospective study . Arthritis Rheum. 43:2000;2025-2033.
18. Mulder A.H., Stegeman C.A., Kallenberg C.G. Activation of granulocytes by anti-neutrophil cytoplasmic antibodies (ANCA) in Wegener's granulomatosis a predominant role for the IgG3 subclass of ANCA . Clin. Exp. Immunol. 101:1995;227-232.
19. Jennette J.C., Falk R.J., Andrassy K., et al. Nomenclature of systemic vasculitides proposal of an international consensus conference . Arthritis Rheum. 37:1994;187-192.
20. Hoffman G.S., Kerr G.S., Leavitt R.Y., Hallahan C.W., Lebovics R.S., Travis W.D., Rottem M., Fauci A.S. Wegener granulomatosis an analysis of 158 patients, Ann . Intern. Med. 116:1992;488-498.
21. Lhote F., Cohen P., Genereau T., Gayraud M., Guillevin L. Microscopic polyangiitis clinical aspects and treatment . Ann. Med. Intern. Paris. 147:(3):1996;165-177.
22. Gayraud M., Guillevin L., le Toumelin P., Cohen P., Lhote F., Casassus P., Jarrousse B. Long-term follow-up of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome analysis of four prospective trials including 278 patients . Arthritis Rheum. 44:2001;666-675.
23. Kikuchi Y., Ikehata N., Tajima O., Yoshizawa N., Miura S. Glomerular lesions in patients with Churg-Strauss syndrome and the anti-myeloperoxidase antibody. Clin. Nephrol. 55:2001;429-435.
24. Rychlík I., Tesař V., Stejskalová A., Stejskal J., Honsová E., Bartůňková J. ANCA-positive Churg-Strauss syndrome with renal failure. Nephrol. Dial. Transplant. 12:1997;837-838.
25. Zhao M.H., Jayne D.R.W., Ardiles L., Culley F., Hodson M.E., Lockwood C.M. Autoantibodies against bactericidal/permaebility-increasing protein (BPI) in cystic fibrosis. Clin. Exp. Immunol. 101:(suppl. 1):1995;38.
26. Zhao M.J., Jayne D.R.X., Ardiles L.G., et al. Autoantibodies against bactericidal/permeability-increasing protein in patients with cystic fibrosis. Q. J. Med. 98:1996;259-265.
27. Zhao M.H., Jones S.J., Lockwood C.M. Bactericidal/permeability-increasing protein (BPI) is an important antigen for anti-neutrophil cytoplasmic antibodies (ANCA) in vasculitis. Clin. Exp. Immunol. 99:1995;49-56.
28. Peter,H.H., Metzger, D., Rump, A., Rother, E., ANCA in diseases other than systemic vasculitis, Clin. Exp. Immunol. Suppl. 12-4 (1993).
29. Saxon A., Shanahan F., Landers C., et al. A distinct subset of antineutrophil cytoplasmic antibodies is associated with inflammatory bowel disease. J. Allergy Clin. Immunol. 86:1990;202-210.
30. Roozendaal C., de Jong M.A., van den Berg A.P., van Wijk R.T., Limburg P.C., Kallenberg C.G. Clinical significance of anti-neutrophil cytoplasmic antibodies (ANCA) in autoimmune liver diseases. J. Hepatol. 32:2000;734-741.
31. Mulder A.H., Horst G., Van Leeuwen M.A., et al. Anti-neutrophil cytoplasmic antibodies in rheumatoid arthritis, characterization and clinical correlation. Arthritis Rheum. 36:1993;1054-1060.
32. de Bandt M., Meyer O., Haim T., Kahn M.F. Antineutrophil cytoplasmic antibodies in rheumatoid arthritis patients. Br. J. Rheumatol. 35:1996;38-43.
33. Vasiliauskiene L., Wiik A., Hoier-Madsen M. Prevalence and clinical significance of antikeratin antibodies and other serological markers in Lithuanian patients with rheumatoid arthritis. Ann. Rheum. Dis. 60:2001;459-466.
34. Locht H., Skogh T., Wiik A. Characterisation of autoantibodies to neutrophil granule constituents among patients with reactive arthritis, rheumatoid arthritis, and ulcerative. colitis. Ann. Rheum. Dis. 59:2000;898-903.
35. Mustila A., Paimela L., Leirisalo-Repo M., Huhtala H., Miettinen A. Antineutrophil cytoplasmic antibodies in patients with early rheumatoid arthritis an early marker of progressive erosive disease . Arthritis Rheum. 43:2000;1371-1377.
36. Bakkaloglu A., Ozen S., Saatci U., et al. Antineutrophil cytoplasmic antibodies in juvenile chronic arthritis. Clin. Rheumatol. 18:1999;304-307.
37. Vittecoq O., Jouen-Beades F., Krzanowska K., et al. Prospective evaluation of the frequency and clinical significance of antineutrophil cytoplasmic and anticardiolipin antibodies in community cases of patients with rheumatoid arthritis. Rheumatology. 39:2000;481-489.
38. Ellenbroek P.M., Oudkerk Pool M., Ridwan B.U., et al. Neutrophil cytoplasmic antibodies (pANCA) in ulcerative colitis. J. Clin. Pathol. 47:1994;257-262.
39. Mulder A.H., Broekroelofs J., Horst G., Limburg P.C., Nelis G.F., Kallenberg C.G.M. Anti-neutrophil cytoplasmic antibodies (ANCA) in inflammatory bowel disease, characterization and clinical correlates. Clin. Exp. Immunol. 95:1994;490-497.
40. Roozendaal C., Kallenberg C.G. Are anti-neutrophil cytoplasmic antibodies (ANCA) clinically useful in inflammatory bowel disease (IBD)? Clin. Exp. Immunol. 116:1999;206-213.
41. Pudifin D.J., Duursma J., Gathiram V., Jackson T.F.H.G. Invasive amoebiasis is associated with the development of anti-neutrophil cytoplasmic antibody. Clin. Exp. Immunol. 97:1994;48-51.
42. Choi H.K., Lamprecht P., Niles J.L., Gross W.L., Merkel P.A. Subacute bacterial endocarditis with positive cytoplasmic antineutrophil cytoplasmic antibodies and anti-proteinase 3 antibodies. Arthritis Rheum. 43:2000;226-231.
43. Diehl V., Schrappe M. Seroprevalence and disease association of antineutrophil cytoplasmic autoantibodies and antigens in HIV infection. Infection. 27:1999;92-96.
44. Ellis E.N., Wood E.G., Berry P. Spectrum of diseases associated with anti-neutrophil cytoplasmic antibodies in pediatric patients. J. Pediatr. 126:(1):1995;40-43.
45. Šedivá A., Kolářová I., Bartůňková J. Antineutrophil cytoplasmic antibodies in children. Eur. J. Pediatr. 157:(12):1998;987-991.
46. Šedivá A., Hoza J., Němcová D., Pospíšilová D., Bartůňková J., Vencovský J. Immunological investigation in children with juvenile chronic arthritis. Med. Sci. Monit. 1:2001;2-7.
47. Šedivá A., Bartůňková J., Kolářová I., Hrušák O., Vávrová V., Macek M. Jr., Lockwood C.h.M., Dunn A.C. Antineutrophil cytoplasmic autoantibodies (ANCA) in children with cystic fibrosis. J. Autoimmun. 11:1998;185-190.
48. Olives J.P., Breton A., Hugot J.P., et al. Antineutrophil cytoplasmic antibodies in children with inflammatory bowel disease prevalence and diagnostic value . J. Pediatr. Gastroenterol. Nutr. 25:1997;142-148.
49. Ruemmele F.M., Targan S.R., Levy G., Dubinsky M., Bran J., Seidman E.G. Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease. Gastroenterology. 115:1998;822-829.
50. Bartůňková J., Kolářová I., Šedivá A., Hölzelová E. Antineutrophil cystoplasmic antibodies (ANCA), anti-Saccharomyces cerevisiae antibodies (ASCA) and specific IgE, to food allergens in children with inflammatory bowel diseases. Clin. Immunol. 102:2002;162-168.
51. Rottem M., Fauci A.S., Hallahan C.W., et al. Wegener's granulomatosis in children and adolescents clinical presentation and outcome . J. Pediatr. 122:1993;26-31.
52. Gencik M., Borgmann S., Zahn R., Albert E., Sitter T., Epplen J.T., Fricke H. Immunogenetic risk factors for anti-neutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis. Clin. Exp. Immunol. 117:(12):1999;412-417.
53. Callea F., Gregorini G., Sinico A., et al. Alpha 1-antitrypsin (AAT) deficiency and ANCA-positive systemic vasculitis genetic and clinical implications . Eur. J. Clin. Invest. 27:1997;696-702.
54. Audrain M., Sesboue R., Baranger T.A., Elliott J., Testa A., Martin J.P., Lockwood C.M., Esnault V.L. Analysis of anti-neutrophil cytoplasmic antibodies (ANCA) frequency and specificity in a sample of 191 homozygous (PiZZ) alpha1-antitrypsin-deficient subjects . Nephrol. Dial. Transplant. 16:2001;39-44.
55. Borgmann S., Endisch G., Urban S., Sitter T., Fricke H. A linkage disequilibrium between genes at the serine protease inhibitor gene cluster on chromosome 14q32.1 is associated with Wegener's granulomatosis. Clin. Immunol. 98:2001;244-248.
56. Meller S., Jagiello P., Borgmann S., Fricke H., Epplen J.T., Gencik M. Novel SNPs in the CD18 gene validate the association with MPO-ANCA+ vasculitis. Genes Immun. 2:2001;269-272.
57. Spencer S.J., Burns A., Gaskin G., Pusey C.D., Rees A.J. HLA class II specificities in vasculitis with antibodies to neutrophil cytoplasmic antigens. Kidney Int. 41:1992;1059-1063.
58. Raynauld J.P., Bloch D.A., Fries J.F. Seasonal variation in the onset of Wegener's granulomatosis, polyarteritis nodosa and giant cell arteritis. J. Rheumatol. 20:1993;1524-1526.
59. Barrett T.G., Taylor C.M., Thomason P., Pall A., Adu D. Environmental trigger for anti-neutrophil cytoplasmic antibodies. Lancet. 342:1993;369-370.
60. Stegeman C.A., Tervaert J.W., Manson W.L., Kallenberg C.G. Chronic nasal carriage of Staphylococcus aureus in Wegener granulomatosis identification of a subgroup more prone to relapses. Ann. Intern. Med. 120:1994;12-17.
61. Hoffman G.S., Sechler J.M., Gallin J.I., et al. Bronchoalveolar lavage analysis in Wegener's granulomatosis a method to study disease pathogenesis . Am. Rev. Respir. Dis. 143:1991;401-407.
62. Lawyer C., Henkle J., Bakir H. Nasal carriage of staphylococcal infection in Wegener granulomatosis. Ann. Intern. Med. 121:1994;74-75.
63. Kallenberg C.G.M., Cohen Tervaert J.W., van der Woude F.J., et al. Autoimmunity to lysosomal enzymes new clues to vasculitis and glomerulonephritis? Immunol. Today. 12:1991;61-64.
64. Gross W.L., Csernok E. Immunodiagnostic and pathophysiologic aspects of antineutrophil cytoplasmic antibodies in vasculitis. Curr. Opin. Rheumatol. 7:1995;11-19.
65. Preston G.A., Falk R.J. ANCA signaling not just a matter of respiratory burst . Kidney Int. 59:2001;1981-1982.
66. Nassberger L., Johansson A.C., Bjorck S., Sjoholm A.G. Antibodies to neutrophil granulocyte myeloperoxidase and elastase autoimmune responses in glomerulonephritis due to hydralazine treatment . J. Intern. Med. 229:1991;261-265.
67. Dolman K.M., Gans R.O., Vervaat T.J., Zevenbergen G., Maingay D., Nikkels R.E., Donker A.J., von dem Borne A.E., Goldschmeding R. Vasculitis and antineutrophil cytoplasmic autoantibodies associated with propylthiouracil therapy. Lancet. 342:1993;651-652.
68. Choi H.K., Merkel P.A., Walker A.M., Niles J.L. Drug-associated antineutrophil cytoplasmic antibody-positive vasculitis prevalence among patients with high titers of antimyeloperoxidase antibodies . Arthritis Rheum. 43:2000;405-413.
69. Elkayam O., Yaron M., Caspi D. Minocycline-induced autoimmune syndromes an overview . Semin. Arthritis Rheum. 28:1999;392-397.
70. Choi H.K., Slot M.C., Pan G., et al. Evaluation of antineutrophil cytoplasmic antibody seroconversion induced by minocycline, sulfasalazine, or penicillamine. Arthritis Rheum. 43:2000;2488-2492.
71. Dunphy J., Oliver M., Rands A.L., et al. Antineutrophil cytoplasmic antibodies and HLA class II alleles in minocycline-induced lupus-like syndrome. Br. J. Dermatol. 142:2000;461-467.
72. Gregorini G., Tira P., Frizza J., D'Haese P.C., Elseviers M.M. ANCA-associated diseases and silica exposure. Clin. Rev. Allergy Immunol. 15:1997;21-40.
73. Tervaert J.W.C., Stegeman C.A., Kallenberg C.G.M. Silicon exposure and vasculitis. Curr. Opin. Rheumatol. 10:1998;12-17.
74. Stratta P., Messuerotti A., Canavese C., Coen M., Luccoli L., et al. The role of metals in autoimmune vasculitis epidemiological and pathogenic study . Sci. Total Environ. 270:2001;179-190.
75. Cojocaru M., Niculescu T., Spataru E. Antineutrophil cytoplasm antibodies in patients with silicosis. Rev. Roum. Med. Int. 34:1996;233-237.
76. Bartůňková J., Kolářová I., Šedivá A., Dvořák D., Pelclová D., Fenclová Z., Jančová E., Tesař V. Does silica cause vasculitis and kidney damage? Clin. Immunol. 99:2001;107.
77. Pelclová D., Fenclová Z., Lebedová J., Kolářová I., Dvořák D., Bartůňková J., et al. Silicosis, asbestosis and ANCA positivity. Eur. Respir. J. 18:(Suppl):2001;437-438.
78. Heeringa P., Brouwer E., Cohen Tervaert J.W., et al. Animal models of anti-neutrophil cytoplasmic antibody associated vasculitis. Kidney Int. 53:1998;253-263.
79. Luzina I.G., Handwerger B.S. Lessons from animal models of vasculitis. Curr. Rheumatol. Rep. 2:2000;369-375.
80. Hong Xiao H., Heeringa P., Hu P., et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J. Clin. Invest. 110:2002;955-963. doi: 10.1172/JCI200215918.
81. Savage C.O.S., Pottinger B.E., Gaskin G., et al. Autoantibodies developing to myeloperoxidase and proteinase 3 in systemic vasculitis stimulate neutrophil cytotoxicity towards cultured endothelial cells. Am J. Pathol. 141:1992;335-342.
82. Haber M.A., Tso A., Taheri S. Wegener's granulomatosis in pregnancy the therapeutic dilemma . Nephrol Dial. Transplant. 14:1999;1789-1791.
83. Ruiz-Arguelles A., Alarcon-Segovia D. Penetration of autoantibodies into living cells, 2000. Isr. Med. Assoc. J. 3:(2):2001;121-126.
84. van der Geld Y.M., Tool A.T., Videler J., et al. Interference of PR3-ANCA with the enzymatic activity of PR3 differences in patients during active disease or remission of Wegener's granulomatosis . Clin. Exp. Immunol. 129:2002;562-570.
85. Elsbach P., Weiss J., Doerfler M., Shu C., Kohn F., Ammons W.S., Kungm A.H., Meszaros K.K., Parent J.B. The bactericidal/permeability increasing protein of neutrophils is a potent antibacterial and anti-endotoxin agent in vitro and in vivo. Prog. Clin. Biol. Res. 388:1994;41-51.
86. Falk R.J., Terrell R.S., Charles L.A., Jennette J.C. Antineutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radical in vitro. Proc. Natl. Acad. Sci. USA. 87:1990;4115-4119.
87. Campanelli D., Melchior M., Fu Y., Nakata M., Shuman H., Nathan C., Gabay J.E. Cloning of cDNA for proteinase 3, a serine protease, antibiotic, and autoantigen from human neutrophils. J. Exp. Med. 172:1990;1709-1715.
88. Bartůňková J., Fučíková T., Tesař V., et al. Antineutrophil cytoplasmic antibody-positive sera inhibit candidacidal activity of granulocytes. Exp. Nephrol. 3:1995;58-60.
89. Bartůňková J., Araujo A., Hrušák O., Šedivá A. Autoimmunity to polymorphonuclears functional consequences of the binding of antibodies to membrane and cytoplasmic target antigens of polymorphonuclear leukocytes . J. Clin. Immunol. 17:1997;455-461.
90. A. Šedívá, H.S. Jethwa, J. Bartůňková, R.J. Falk, J.C. Jennette, ANCA mediated inhibition of pseudomonadocidia in children with cystic fibrosis, Microbes Infect. (2002) in press.
91. Charles L.A., Falk R.J., Jennette J.C. Reactivity of antineutrophil cytoplasmic autoantibodies with mononuclear phagocytes. J. Leukocyte Biol. 51:1992;65-68.
92. Weidner S., Neupert W., Goppelt-Struebe M., Rupprecht H.D. Antineutrophil cytoplasmic antibodies induce human monocytes to produce oxygen radicals in vitro. Arthritis Rheum. 44:2001;1698-1706.
93. Harper L., Cockwell P., Dwoma A., Savage C. Neutrophil priming and apoptosis in anti-neutrophil cytoplasmic autoantibody-associated vasculitis. Kidney Int. 59:2001;1729-1738.
94. Rauova L., Gilburd B., Zurgil N., lank M., Guegas L.L., et al. Induction of biologically active antineutrophil cytoplasmic antibodies by immunization with human apoptotic polymorphonuclear leukocytes. Clin. Immunol. 103:2002;69-78.
95. Atkins R.C. Interleukin-1 in crescentic glomerulonephritis. Kidney Int. 48:1995;576-586.
96. Noronha I.L., Kruger C., Andrassy K., et al. In situ production of TNF-α, IL-1β and IL-2R in ANCA-positive glomerulonephritis. Kidney Int. 43:1993;682-692.
97. Tesař V., Mašek Z., Rychlík I., Bartůňková J., Stejskalová A., Žabka J., et al. Cytokines and adhesion molecules in ANCA positive vasculitis and lupus nephritis. Cardionephrol. Bios. 3:1995;549-551.
98. Tesař V., Jelínková E., Mašek Z., Jirsa M. Jr., Žabka J., Bartůňková J., et al. Influence of plasma exchange on serum levels of cytokines and adhesion molecules in ANCA-positive renal vasculitis. Blood Purif. 16:1998;72-80.
99. Tesař V., Mašek Z., Rychlík I., Merta M., Bartůňková J., Stejskalová A., et al. Cytokines and adhesion molecules in renal vasculitis and lupus nephritis. Nephrol. Dial. Transplant. 13:1998;1662-1667.
100. Falk R.J., Nachman P.H., Hogan S.L., Jennette J.C. ANCA glomerulonephritis and vasculitis a Chapel Hill perspective . Semin Nephrol. 20:2000;233-243.
101. Luqmani R. Measuring disease activity and outcomes in clinical studies [review]. Clev. Clin. J. Med. 69:(Suppl. 2):2002;100-102. SII.
102. Scott D.G.I. Epidemiology of systemic vasculitis increasing incidence? Clin. Exp. Immunol. 120:(Suppl):2000;19-20.
103. Hagen E.C., Daha M.R., Hermans J., et al. Diagnostic value of standardized assays for antineutrophil cystoplasmic antibodies in idiopathie systemic vasculitis. Kidney Int. 53:1998;743-753.
104. Savige J., Gillis D., Davies D., et al. International Consensus Statement on testing and reporting of antineutrophil cytoplasmic antibodies (ANCA). Am. J. Clin. Pathol. 111:1999;507-513.
105. Rao J.K., Weinberger M., Oddone E.Z. The role of antineutrophil cytoplasmic antibody (cANCA) testing in the diagnosis of Wegener's granulomatosis. Ann. Intern. Med. 123:1995;925-932.
106. Jennings C.R., Jones N.S., Dugar J., et al. Wegener's granulomatosis - a review of diagnosis and treatment in 53 subjects. Rhinology. 36:1998;188-191.
107. Paulsen J.I., Rudert H. Manifestations of primary vasculitis in the ENT region. Z. Rheumatol. 60:2001;219-225.
108. Wiik A. Methods for the detection of anti-neutrophil cytoplasmic antibodies recommendations for clinical use of ANCA serology and laboratory efforts to optimize the informative value of ANCA test results . Springer Semin. Immunopathol. 23:(3):2001;217-229.
109. Russell K.A., Wiegert E., Schroeder D.R., Homburger H.A., Specks U. Detection of anti-neutrophil cytoplasmic antibodies under actual clinical testing conditions. Clin. Immunol. 103:2002;196-203.
110. Cohen Tervaert J.W., Van der Woude F.J., Fauci A.S., et al. Association between active Wegener's granulomatosis and anticytoplasmic antibodies. Arch. Intern. Med. 149:1989;2461-2465.
111. Jayne D.R., Gaskin G., Pusey C.D., Lockwood C.M. ANCA and predicting relapse in systemic vasculitis. Q. J. Med. 88:1995;127-133.
112. Gaskin G., Savage C.O.S., Ryan J.J., et al. Anti-neutrophil cytoplasmic antibodies and disease activity during longterm follow up of 70 patients with systemic vasculitis. Nephrol. Dial. Transplant. 6:1991;689-694.
113. Stegeman C.A., Cohen Tervaert J.W., Slutter W.J., et al. Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener's granulomatosis. Ann. Intern. Med. 120:1994;12-17.
114. Cohen Tervaert J.W., Huitema M.G., Hene R.J., et al. Prevention of relapses in Wegener's granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre. Lancet. 336:1990;709-711.
115. Kerr G.S., Fleisher T.A., Hallahan C.W., et al. Limited prognostic value of changes in antineutrophil cytoplasmic antibody titer in patients with Wegener's granulomatosis. Arthritis Rheum. 36:1993;365-371.
116. Hoffman G.S., Kerr G.S. Rise in ANCA titer to treat or not to treat . Am. J. Med. 98:1995;102-103.
117. Mulder A.H., Stegeman C.A., Kallenberg C.G. Activation of granulocytes by anti-neutrophil cytoplasmic antibodies (ANCA) in Wegener's granulomatosis a predominant role for the IgG3 subclass of ANCA . Clin. Exp. Immunol. 101:1995;227-232.
118. Muller Kobold A.C., Kallenberg C.G., Cohen Tervaert J.W. Leucocyte membrane expression of proteinase 3 correlates with disease activity in patients with Wegener's granulomatosis. Br. J. Rheumatol. 37:1998;901-907.